Education
About Us
Working with TipRanks
Follow Us
Giant Biogene Holding Co. Ltd. (HK:2367)
:2367
RESEARCH TOOLSreports
Total Valuation
Giant Biogene Holding Co. Ltd. has a market cap or net worth of HK$69.89B. The enterprise value is HK$39.93B.
Market CapHK$69.89B
Enterprise ValueHK$39.93B
Share Statistics
Giant Biogene Holding Co. Ltd. has 1.04B shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1.04B
Owened by Insiders
Owened by Instutions
Financial Efficiency
Giant Biogene Holding Co. Ltd.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per EmployeeHK$3,081,967.861
Profits Per EmployeeHK$1,228,887.088
Employee Count1,758
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Giant Biogene Holding Co. Ltd. is ―. Giant Biogene Holding Co. Ltd.’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Giant Biogene Holding Co. Ltd. had revenue of HK$5.42B and earned HK$2.16B in profits. Earnings per share was HK$2.20.
RevenueHK$5.42B
Gross ProfitHK$4.49B
Operating IncomeHK$2.43B
Pretax IncomeHK$2.61B
Net IncomeHK$2.16B
EBITDA2.48B
Earnings Per Share (EPS)2.20
Cash Flow
In the last 12 months, operating cash flow was HK$2.35B and capital expenditures -HK$224.43M, giving a free cash flow of HK$2.13B billion.
Operating Cash FlowHK$2.35B
Free Cash FlowHK$2.13B
Free Cash Flow per ShareHK$2.06
Dividends & Yields
Giant Biogene Holding Co. Ltd. pays an annual dividend of HK$0.97, resulting in a dividend yield of 0.70%
Dividend Per ShareHK$0.97
Dividend Yield0.70%
Payout Ratio22.36%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.95
52-Week Price Change61.27%
50-Day Moving Average64.65
200-Day Moving Average51.04
Relative Strength Index (RSI)64.53
Average Volume (3m)4.83M
Important Dates
Giant Biogene Holding Co. Ltd. upcoming earnings date is Sep 1, 2025, TBA.
Last Earnings DateMar 26, 2025
Next Earnings DateSep 1, 2025
Ex-Dividend DateJun 17, 2025
Financial Position
Giant Biogene Holding Co. Ltd. as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Giant Biogene Holding Co. Ltd. has paid HK$455.63M in taxes.
Income TaxHK$455.63M
Effective Tax Rate―
Enterprise Valuation
Giant Biogene Holding Co. Ltd. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Giant Biogene Holding Co. Ltd. has HK$6.06B in cash and marketable securities with HK$1.46M in debt, giving a net cash position of -HK$6.06B billion.
Cash & Marketable SecuritiesHK$6.06B
Total DebtHK$1.46M
Net Cash-HK$6.06B
Net Cash Per Share-HK$5.85
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Giant Biogene Holding Co. Ltd. is HK$78.99, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$78.99
Price Target Upside15.57%
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast
EPS Growth Forecast